RESUMO
Doenças cardiovasculares são as principais complicações fatais da doença renal crônica, tanto para pacientes em terapia renal substitutiva quanto para aqueles em tratamento conservador. A análise de seus fatores de risco, abordagem diagnóstica e adequado tratamento são fundamentais para a redução de mortalidade associada a essas complicações. Neste artigo de revisão são discutidos aspectos de fisiopatologia, métodos de investigação e abordagem terapêutica da doença cardiovascular na doença renal crônica.
Cardiovascular diseases are the major fatal complications of chronic kidney disease, both for patients in renal replacement therapy and for those on dialysis. The analysis of their risk factors, diagnosis and appropriate treatment are key to reducing mortality associated with these complications. In this review we discuss aspects of pathophysiology, research methods and therapeutic approach to cardiovascular disease in chronic kidney disease.
Assuntos
Humanos , Masculino , Feminino , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Hipertrofia Ventricular Esquerda/complicações , Uremia/complicações , Avaliação em Saúde/métodosRESUMO
The usual drug used in the Wada test is amobarbital, but it is not available in Brazil. Propofol was already used by Bazin et al. in 1998, and in their report the test resulted good in the absence of any adverse effect. We report the use of propofol as the anesthetic for the Wada test. The test was carried out in a 26 years old woman with temporal medial lobe epilepsy refractory to medical treatment. Language functions and memory were tested after injection in both hemispheres by three procedures (Seattle, Montreal and Interview procedures). Propofol showed to be good to carry on the Wada test.